Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.

S D Webster1, A J Tenner, T L Poulos

  • 1Department of Molecular Biology and Biochemistry, University of California Irvine, 92697-3900, USA.

Neurobiology of Aging
|December 10, 1999
PubMed
Summary

Alzheimer's disease (AD) models show limited neuronal loss. Chronic complement (C') activation by beta-amyloid (A beta) may cause neuron death, but mouse models do not fully replicate human AD inflammation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.

Neurobiology of disease·2019
Same author

CD200 modulates macrophage cytokine secretion and phagocytosis in response to poly(lactic co-glycolic acid) microparticles and films.

Journal of materials chemistry. B·2017
Same author

Synthesis and release of sucrose by the aleurone layer of barley: Regulation by gibberellic acid.

Planta·2014
Same author

Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Journal of neuroimmunology·2010
Same author

DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Gene therapy·2009
Same author

Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits.

Journal of neuroimmunology·2009

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Neuronal loss is a hallmark of Alzheimer's disease (AD), yet it is not consistently observed in current transgenic models.
  • Chronic activation of the complement system (C') by beta-amyloid (A beta) is a proposed mechanism driving neurodegeneration in AD.
  • A beta binds to the C1q A-chain, initiating complement activation.

Purpose of the Study:

  • To investigate the differences in complement activation between mouse and human systems in response to beta-amyloid.
  • To evaluate the efficacy of a human-derived peptide in blocking complement activation by A beta in a murine model.

Main Methods:

  • Comparison of complement activation by A beta in mouse and human serum.
  • Assessment of a peptide inhibitor based on the human C1q A-chain sequence in blocking A beta-induced complement activation.

Related Experiment Videos

  • Analysis of A beta binding to the C1q A-chain in mouse models.

    • Main Results:

    • Human complement (C') is activated more effectively by A beta than mouse complement.
    • A peptide inhibitor based on the mouse A-chain sequence failed to block A beta-induced C' activation, unlike the human peptide.
    • Significant differences exist between mouse and human C1q A-chain sequences, impacting A beta binding and C' activation.

    Conclusions:

    • Current transgenic mouse models may not fully recapitulate the complement-mediated inflammation and neurodegeneration seen in human AD.
    • Genetic modifications may be required in murine models to accurately replicate AD-related inflammatory processes.
    • Understanding species-specific differences in complement activation is crucial for developing effective AD therapies.